Skip to main content
. 2016 Sep 17;7(50):82609–82619. doi: 10.18632/oncotarget.12089

Table 1. Stage Tis, Ta mRNA Cohort – 189 Patients.

Characteristic N (%)
Median Age (IQR) 67 (58-74)
Male 154 (81)
High Grade* 64 (34)
CIS+ 17 (9)
EORTC High-Risk Group 67 (35)
Median Follow-up in Years (IQR) 4.8 (3.4-6.7)
Progression to T2 21 (11)
Deaths 57 (30)
*

2004 World Health Organization grade definitions

** European Organisation for Research and Treatment of Cancer